Open AccessBortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)
Author(s) -
Sven Trelle,
Orhan Sezer,
Ralph Naumann,
Mathias Rummel,
Ulrich Keller,
Andreas Engert,
Peter Borchmann
Publication year - 2007
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.10797
Subject(s) - bortezomib , dexamethasone , medicine , lymphoma , oncology , stage (stratigraphy) , multiple myeloma , paleontology , biology
We conducted a two-stage phase II study to investigate the activity of bortezomib and dexamethasone in patients with relapsed Hodgkin's lymphoma. The study was prematurely closed after the first stage with twelve enrolled patients because no response was observed. A meta-analysis of all four available studies evaluating bortezomib in this population showed no activity of bortezomib (combined response rate: 0.03; 95%-CI: 0.01 to 0.12).